Oral small-molecule GLP-1 receptor agonistStructure Therapeutics

Aleniglipron

Aleniglipron (GSBR-1290) is an oral small-molecule GLP-1 receptor agonist from Structure Therapeutics, evaluated for weight loss in obesity in the Phase 2b ACCESS study.

Also known as: GSBR-1290

Forecast a trial in the Arena Browse all benchmarks

Trials tracked

Resolved

Indications

Targets

Aleniglipron forecasting benchmarks

1 benchmark

ResolvedPhase 2b

ACCESS (aleniglipron) Phase 2b obesity

Aleniglipron · Obesity

Dec 8, 2025Clinical Trials

Mechanism & molecular targets

GLP-1R· gene

Indications studied

Obesity

Developed by

Structure Therapeutics· STTX

About Aleniglipron

What is Aleniglipron?

Aleniglipron (GSBR-1290) is an oral small-molecule GLP-1 receptor agonist from Structure Therapeutics, evaluated for weight loss in obesity in the Phase 2b ACCESS study. It is a oral small-molecule glp-1 receptor agonist developed by Structure Therapeutics.

What does Aleniglipron target?

Aleniglipron acts on GLP-1 receptor (GLP1R).

How well do AI models predict Aleniglipron trial outcomes?

Open any benchmark below to see the full model leaderboard scored by accuracy, Brier score, and log loss. Models forecast each readout before it is public, so the scores reflect genuine predictive skill rather than hindsight.

References

Keep exploring

All benchmarks Diseases Companies Targets & genes